The highly esteemed Dermatology Foundation Clinical
Symposia, held in February 2015, provided the latest clinically relevant
research and information on various dermatologic disorders, including atopic
dermatitis (AD). Lawrence D. Eichenfield, MD presented the keynote address on Improving Outcomes in Atopic Dermatitis
that reviewed research on the efficacy of several AD treatments, including the
use of bleach bath and a recently introduced sodium hypochlorite wash.
The CLEAN study (Herbert A et al 2014 AAD Poster #7728), found
that the use of CLn® Body Wash (a
sodium hypochlorite-formulated wash) led to significant decrease in AD in 40
pediatric study subjects. Specifically, the study found that when CLn was added
to standard AD treatment disease severity scores decreased 34-44% at 6 weeks when compared to baseline.
The results of using a sodium hypochlorite wash in staphylococcus
aureus colonized pediatric patients with AD, with a percentage mean reduction
from baseline at weeks 2 and 6, are depicted in the table below.
Assessment Tool
|
Eczema
Area and Severity Index (EASI)
|
Body
Surface Areas (BSA)
|
Investigator
Global Assessment (IGA)
|
Pruritus
Visual Analog Scale (VAS)
|
2 weeks
|
-34.9%
|
-23.8%
|
-22.8%
|
-31.2%
|
6 weeks
|
-43.8%
|
-35.0%
|
-33.8%
|
-36.8%
|
The Dermatology Foundation’s newsletter, Dermatology Focus, profiled Dr.
Eichenfield’s review of AD, including the significant evidence-based progress
in using current treatment modalities, the current efforts to fill important
gaps affecting successful patient management, and the development of
innovative, targeted therapies in the treatment of AD. Those factors that
enable patients to achieve effective disease control—i.e., minimized rash,
itch, allergies, comorbidities, and drug side effects and toxicities—were also
highlighted.
“So much of what we encounter in AD is inadequate care of
patients who can in reality be appropriately managed, and we want to minimize
the percentage of patients who are inadequately controlled,” stated Dr.
Eichenfield during the keynote address.
Atopic dermatitis is the most common form of eczema. Eczema
is an inflammatory skin condition that causes skin to become dry, itchy, and
red. CLn® Body Wash is one product in the family
of CLn® Skin Care products that was created to elevate the life quality of people with impaired
skin. All products in the line are dermatologist-developed and clinically
tested. CLn® BodyWash is designed to
cleanse skin prone to eczema, acne, and folliculitis without irritation and
aids in the reduction of body odor. For more information on CLn® Skin Care, please visit: www.CLnWash.com.
References
Dermatology Foundation. DF clinical symposia: Proceedings
2015—Part I. Keynote address. Dermatology
Focus. 2015; 34(1): 1-2. Retrieved November 2, 2015, from http://dermatologyfoundation.org/pdf/pubs/DF_Spring_2015.pdf.
Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK. Topical
hypochlorite ameliorates NF-kB-mediated skin diseases in mice. J Clin Invest. 2013; 123(12): 5361-5370. doi: 10.1172/JCI70895.
No comments:
Post a Comment